Compare PROF & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | DHY |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.8M | 240.4M |
| IPO Year | 2017 | 1998 |
| Metric | PROF | DHY |
|---|---|---|
| Price | $5.60 | $16.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.14 | N/A |
| AVG Volume (30 Days) | 264.5K | ★ 403.5K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $71.10 | N/A |
| Revenue Next Year | $58.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $4.91 | $1.61 |
| 52 Week High | $8.95 | $16.67 |
| Indicator | PROF | DHY |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 89.16 |
| Support Level | $4.97 | $15.90 |
| Resistance Level | $7.19 | $16.30 |
| Average True Range (ATR) | 0.44 | 0.17 |
| MACD | -0.07 | -0.35 |
| Stochastic Oscillator | 3.23 | 44.26 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.